TY - JOUR AU - Rosenblatt, Jacalyn AU - Avigan, David PY - 2012 TI - Targetting the PD-L1/PD-1 axis holds promise in the treatment of malignancy JF - Translational Cancer Research; Vol 1, No 4 (December 22, 2012): Translational Cancer Research (Particle Beam Therapy II) Y2 - 2012 KW - N2 - Tumor cells create an immunologic milieu characterized by the disruption of effective antigen presentation, loss of effector cell function and complexity, and upregulation of pathways that promote tolerance and T cell anergy (1,2). A critical element of tumor mediated immunosuppression is the presence of the negative checkpoint molecules CTLA-4 and PDL-1/PD-1 that inhibit immune activation and the expansion of antigen specific T cells (3). UR - https://tcr.amegroups.org/article/view/788